The Technical Analyst
Zentalis Pharmaceuticals [ZNTL]
Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
Zentalis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
14.08% $23.42
Last updated: 16 May 2022 @ 11:40 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 092.07 mill |
| EPS: | -3.72 |
| P/E: | 0.000 |
| Earnings Date: | Aug 10, 2022 |
| SharesOutstanding: | 46.63 mill |
| Avg Daily Volume: | 0.687 mill |
| RATING 2022-05-13 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$25.54 (9.07%) $2.12 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $2.90 ( +/- 14.12%) Range: 17.63 - 23.43 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-04-11 | Bunker Kevin D. | Sell | 100 | Common Stock |
| 2022-04-11 | Bunker Kevin D. | Sell | 300 | Common Stock |
| 2022-04-11 | Bunker Kevin D. | Sell | 4 600 | Common Stock |
| 2022-04-05 | Gallagher Cam | Sell | 100 | Common Stock |
| 2022-04-05 | Gallagher Cam | Sell | 2 196 | Common Stock |
| INSIDER POWER |
|---|
| -43.75 |
| Last 100 transactions |
| Buy: 200 338 | Sell: 531 799 |
Forecast:
13:19 - $23.31
Live Trading Signals (every 1 min)
Forecast
1: 11:49 - $23.33
Forecast 2: 12:39 - $22.66
Forecast 3: 13:19 - $23.31
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $23.42 (14.08% ) |
| Volume | 1.741 mill |
| Avg. Vol. | 0.687 mill |
| % of Avg. Vol | 253.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ZNTL
275 Signals | Accuracy: 26.55% | Accuracy Buy: 28.47% | Accuracy Sell: 24.64%
Avg return buy: -0.07 % | Avg return sell: -0.04 %
$1 invested is now $0.91 or -9.36% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 10:37 | sell | $25.00 | $25.38 @ May 16 - 10:39 | 1.52% |
|---|---|---|---|---|
| May 16 - 09:58 | buy | $22.22 | $21.92 @ May 16 - 10:02 | -1.35% |
| May 16 - 09:54 | sell | $21.92 | $22.22 @ May 16 - 09:58 | 1.37% |
| May 16 - 09:36 | buy | $21.48 | $21.95 @ May 16 - 09:52 | 2.19% |
| May 13 - 15:35 | sell | $21.29 | $21.31 @ May 16 - 09:35 | 0.09% |
| May 13 - 15:23 | buy | $21.40 | $21.30 @ May 13 - 15:34 | -0.49% |
| May 13 - 15:20 | sell | $21.29 | $21.40 @ May 13 - 15:22 | 0.52% |
| May 13 - 15:18 | buy | $21.33 | $21.29 @ May 13 - 15:20 | -0.19% |
| May 13 - 15:16 | sell | $21.30 | $21.33 @ May 13 - 15:18 | 0.14% |
| May 13 - 14:52 | buy | $21.12 | $21.31 @ May 13 - 15:15 | 0.90% |
ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York.
Latest Press Releases
2022-05-16 07:28:00 - Press Release
Zentalis Pharmaceuticals Announces Pricing Of Underwritten Offering Of Common Stock
New york and san diego, may 16, 2022 (globe newswire) -- zentalis pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten offering of 10,330,000 shares of its common stock at an offering price of $19.38 per share, for total gross proceeds of approximately $200.2 million, before deducting underwriting discounts and commissions and offering expenses payable by zentalis. all of the common stock is being offered by zentalis. the offering is expected to close on may 18, 2022, subject to customary closing conditions...
2022-05-05 07:00:00 - Press Release
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results And Operational Update
Announced initial data on zn-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on zn-c3 in uterine serous carcinoma (usc) at aacr
2022-04-27 07:00:00 - Press Release
Zentalis Pharmaceuticals Announces $25 Million Equity Investment From Pfizer
Zentalis and pfizer plan to jointly advance the clinical development of zn-c3, a selective wee1 inhibitor designed to induce synthetic lethality in cancer cells
2022-04-11 16:01:00 - Press Release
Zentalis Pharmaceuticals Announces Overview Of Clinical And Preclinical Data Presented At Aacr
Zn-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an orr of 30.2% across all evaluable chemotherapy cohorts
2022-04-08 13:00:00 - Press Release
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data On Zn-c3, Its Wee1 Inhibitor, In Patients With Advanced Ovarian Cancer At Aacr
Zn-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an orr of 30.2% across all evaluable chemotherapy cohorts
Latest News
2022-04-27 10:19:02 - Benzinga
Pfizer Injects $25M Via Equity In Zentalis Pharma
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE: PFE) for $25 million. The offering is expected to close by April 29.
2022-04-19 11:17:51 - Zacks Investment Research
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks
The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-03-09 16:01:00 - GlobeNewsWire
Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
NEW YORK and SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will present a corporate presentation at the Oppenheimer Annual Healthcare Conference on Wednesday, March 16, 2022 at 10:00 a.m. ET.
2022-03-08 16:30:00 - GlobeNewsWire
Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022
Updated data from Phase 1 expansion cohort of ZN-c3 in uterine serous carcinoma (USC) will be presented during a mini symposium session Updated data from Phase 1 expansion cohort of ZN-c3 in uterine serous carcinoma (USC) will be presented during a mini symposium session
2022-02-03 07:00:00 - GlobeNewsWire
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.
2021-09-13 07:00:00 - GlobeNewsWire
Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma
2021-09-01 07:00:00 - GlobeNewsWire
Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3
NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the publication of the discovery of ZN-c3, the Company's highly potent and selective WEE1 inhibitor candidate, in the Journal of Medicinal Chemistry.
2021-08-12 07:00:00 - GlobeNewsWire
Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles
2021-08-02 07:30:00 - GlobeNewsWire
Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma
NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the first patient has been dosed in the Phase 2 trial of ZN-c3, the Company's oral WEE1 inhibitor product candidate, in adult women with recurrent or persistent uterine serous carcinoma (USC). Following an end-of-Phase 1 meeting, the U.S. Food and Drug Administration agreed in principle that ZN-c3 has the potential for an accelerated approval pathway based on the Phase 2 global study design in USC.
2021-08-02 07:00:00 - GlobeNewsWire
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
Proceeds will be used to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China Proceeds will be used to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China